Therapeutic Drug Monitoring
Omalizumab (Xolair®) ELISA Kit
- SKU:
- HUMB00039
- Product Type:
- ELISA Kit
- ELISA Type:
- Biosimilar ELISA
- Biosimilar ELISA Type:
- Free drug
- Applications:
- ELISA
- Reactivity:
- Human
- Analytes:
- Omalizumab (Xolair®)
- Research Area:
- Anti-Allergy and Asthma
Description
Omalizumab (Xolair®) ELISA Kit
Enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of Omalizumab (Xolair®) in serum and plasma. Assay Genie omalizumab ELISA has been especially developed for the quantitative analysis omalizumab in serum and plasma samples and is for research use only.
Omalizumab (Xolair®) ELISA Kit test principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtitre plate coated with the reactant specific for omalizumab (Xolair®). Following incubation wells are washed and then horse radish peroxidase (HRP) conjugate is added and binds to omalizumab. After incubation, the wells are washed, and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of omalizumab (Xolair®) in the sample or standard. Results of samples can be determined directly using the standard curve.
Omalizumab (Xolair®) ELISA Product Information
| Information | Description |
| Application | Free drug |
| Required Volume (uL) | 10 |
| Total Time (min) | 70 |
| Sample Type | Serum, Plasma |
| Number of Assays | 96 |
| Detection Limit (ng/mL) | 10 (ng/mL) |
| Spike Recovery (%) | 85-115% |
| Shelf Life (year) | 1 |
| Alternative Names | IgG1k mAb Xolair |
Omalizumab (Xolair®) - Key Information
Omalizumab (Xolair®) mode of action
Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Omalizumab (Xolair) is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. Omalizumab (Xolair) inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FcεRI-bearing cells limits the degree of release of mediators of the allergic response. Omalizumab does not bind to cell surface IgE, so it does not directly activate mast cells or basophils. The decrease in free IgE levels results in a reduced amount of FcεRI receptors on mast cells, basophils, and antigen-presenting cells.
Omalizumab (Xolair®) uses
Omalizumab is used to treat severe, persisten asthma. Omalizumab binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. Most likely removed by opsonization via the reticuloendothelial system. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.
Omalizumab (Xolair®) ELISA Kit Contents
| Size | Kit Contents |
| 1 x 12 x 8 | Microtiter Plate Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with reactant |
| 7 x 0.3 mL | Omalizumab Standards A-E, High Level Control, Low Level Control 1000; 300; 100; 30 and 0 ng/mL Ready to use. Used for construction of the standard curve. Contains omalizumab (Xolair®), human serum, stabilizer and <0.1% NaN3 |
| 1 x 50 mL | Assay Buffer |
| 1 x 12 mL | Peroxidase Conjugate |
| 1 x 12 mL | TMB Substrate Solution |
| 1 x 12 mL | TMB Stop Solution |
| 1 x 50 mL | Wash Buffer concentrate (20x) |
| 2 x 1 | Adhesive Foil |
Omalizumab (Xolair®) ELISA Protocol
| Steps | Protocol |
| 1 | Pipette 100µl of Assay Buffer non-exceptionally into each of the wells to be used. |
| 2 | Pipette 10 µL of each ready-to use Standards, High Level Control, Low Level Control and Diluted Samples into the respective wells of microtiter plate. Wells |
| 3 | Cover the plate with adhesive foil. Incubate 30 min at room temperature (18- 25°C). |
| 4 | Remove adhesive foil. Discard incubation solution. Wash plate 3 times each with 300µL of diluted. Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel. |
| 5 | Pipette 100 µL of ready-to use Peroxidase Conjugate into each well. |
| 6 | Cover the plate with adhesive foil. Incubate 30 min at room temperature (18- 25°C). |
| 7 | Remove adhesive foil. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel. |
| 8 | Pipette 100 µL of TMB Substrate Solution into each well. |
| 9 | Incubate 10 min (without adhesive foil) at room temperature (18-25°C) in the dark |
| 10 | Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Colour changes from blue to yellow. |
| 11 | Measure optical density with a photometer at 450/650 nm within 30 min after pipetting of the Stop Solution. |
Trademarks
Xolair® is a trademark of Novartis AG.
Related Products
Infliximab (Remsima®) ELISA Kit
Therapeutic Drug Monitoring
Ranibizumab (Lucentis®) ELISA Kit
Therapeutic Drug Monitoring
Etanercept (Enbrel®) ELISA Kit
Therapeutic Drug Monitoring